We are live on ! Find out more
GPCR icon

Structure Therapeutics

150 hedge funds and large institutions have $981M invested in Structure Therapeutics in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 50 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more call options, than puts

Call options by funds: $12.4M | Put options by funds: $11.7M

8% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 50

2.8% less ownership

Funds ownership: 35.31%32.51% (-2.8%)

9% less funds holding

Funds holding: 164150 (-14)

36% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 36

40% less capital invested

Capital invested by funds: $1.65B → $981M (-$665M)

80% less funds holding in top 10

Funds holding in top 10: 51 (-4)

Holders
150
Holders Change
-14
Holders Change %
-8.54%
% of All Funds
2.01%
Holding in Top 10
1
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-80%
% of All Funds
0.01%
New
23
Increased
46
Reduced
50
Closed
36
Calls
$12.4M
Puts
$11.7M
Net Calls
+$750K
Net Calls Change
-$10.1M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$135M +$136K +5,569 +0.1%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$102M -$4.78M -195,039 -3%
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$86.1M +$4.78M +195,306 +5%
DTC
4
Deep Track Capital
Connecticut
$71M +$31.8M +1,300,000 +46%
Capital Research Global Investors
5
Capital Research Global Investors
California
$37.5M -$33.6M -1,373,196 -39%
VPC
6
Vestal Point Capital
New York
$31M +$1.57M +63,990 +4%
BI
7
BVF Inc
California
$30.7M
Capital International Investors
8
Capital International Investors
California
$28M -$1.35K -55 -0%
RCM
9
RA Capital Management
Massachusetts
$26.3M
Ameriprise
10
Ameriprise
Minnesota
$25.7M +$1.51M +61,757 +4%
DCM
11
Driehaus Capital Management
Illinois
$22M -$19.2M -784,667 -38%
Federated Hermes
12
Federated Hermes
Pennsylvania
$20.3M -$21.4M -875,010 -43%
Fidelity International
13
Fidelity International
Bermuda
$19.9M -$3.66M -149,575 -12%
RSCM
14
Rock Springs Capital Management
Maryland
$19.6M +$1.27M +52,016 +5%
TCM
15
TCG Crossover Management
California
$18.4M
Citadel Advisors
16
Citadel Advisors
Florida
$17.2M -$11.9M -486,999 -33%
Millennium Management
17
Millennium Management
New York
$13.7M +$959K +39,146 +5%
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$13.5M -$15.1M -617,133 -44%
Principal Financial Group
19
Principal Financial Group
Iowa
$13.1M -$843K -34,427 -4%
Franklin Resources
20
Franklin Resources
California
$12.8M +$50.5K +2,062 +0.3%
CCM
21
Catalio Capital Management
New York
$12.2M +$3.32M +135,469 +24%
CC
22
Casdin Capital
New York
$12.1M
Morgan Stanley
23
Morgan Stanley
New York
$12M +$7.48M +305,263 +79%
O
24
OrbiMed
New York
$11.3M
BlackRock
25
BlackRock
New York
$9.81M -$1.08M -44,080 -7%

GPCR Hedge Fund Activity: Q1 2025 in Review

150 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q1 2025, worth a combined $981M — down 40% from $1.65B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of GPCR and 23 opened new positions — a net loss of 13 holders — while 50 trimmed existing stakes and 46 added.

The largest buyer was Deep Track Capital, adding an estimated $31.8M. The largest seller was Capital Research Global Investors, cutting an estimated $33.6M.

  • 150 institutional investors held Structure Therapeutics (GPCR) as of Q1 2025, down from 164 in Q4 2024.
  • Funds reported $981M of Structure Therapeutics stock for Q1 2025, down 40% quarter-over-quarter.
  • 23 funds opened new Structure Therapeutics positions in Q1 2025 and 36 closed out, a net change of -13 holders.
  • The largest Structure Therapeutics buyer in Q1 2025 was Deep Track Capital, an estimated $31.8M added.
  • The largest Structure Therapeutics seller in Q1 2025 was Capital Research Global Investors, an estimated $33.6M sold.

Based on aggregated 13F filings for Q1 2025.